Artivion's (AORT) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Artivion's stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating ongoing concerns about the company's performance.
• Despite the negative outlook from Weiss Ratings, some analysts have issued more favorable ratings, with a price target increase to $50.00 from Canaccord Genuity, which rates it a "buy."
• Artivion's recent quarterly earnings exceeded expectations, reporting $0.24 earnings per share against an estimate of $0.11 and experiencing a 15.3% increase in revenue year-over-year.

Artivion (NYSE:AORT - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity Group lifted their price target on shares of Artivion from $41.00 to $50.00 and gave the stock a "buy" rating in a report on Monday, September 29th. LADENBURG THALM/SH SH lowered Artivion from a "buy" rating to a "neutral" rating and boosted their target price for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. JMP Securities upped their price target on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research report on Friday, August 8th. Stifel Nicolaus lifted their price objective on Artivion from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Monday, September 29th. Finally, Oppenheimer restated an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $43.13.

Artivion Stock Performance

Shares of Artivion stock traded up $0.49 during trading hours on Wednesday, hitting $41.00. 213,923 shares of the company's stock traded hands, compared to its average volume of 441,750. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -97.62 and a beta of 1.67. Artivion has a 12-month low of $21.97 and a 12-month high of $45.07. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The company has a fifty day simple moving average of $40.73 and a 200-day simple moving average of $32.24.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Artivion will post 0.37 EPS for the current fiscal year.

Insider Activity

In other Artivion news, CEO James P. Mackin sold 12,500 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the transaction, the chief executive officer directly owned 852,783 shares in the company, valued at $36,089,776.56. This represents a 1.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 23,356 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total value of $1,004,541.56. Following the transaction, the senior vice president directly owned 172,129 shares of the company's stock, valued at $7,403,268.29. The trade was a 11.95% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 74,858 shares of company stock worth $3,250,129. Company insiders own 8.10% of the company's stock.

Hedge Funds Weigh In On Artivion

Institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its holdings in shares of Artivion by 1.9% during the 2nd quarter. Franklin Resources Inc. now owns 29,263 shares of the company's stock worth $910,000 after acquiring an additional 533 shares during the last quarter. Smartleaf Asset Management LLC raised its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. Illinois Municipal Retirement Fund lifted its stake in Artivion by 3.1% during the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock worth $504,000 after purchasing an additional 611 shares during the last quarter. MCF Advisors LLC boosted its holdings in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Finally, Creative Planning increased its position in shares of Artivion by 5.6% during the 2nd quarter. Creative Planning now owns 14,272 shares of the company's stock valued at $444,000 after purchasing an additional 753 shares during the last quarter. Institutional investors own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.